Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics (NASDAQ: IMTX), a biopharmaceutical firm focused on precision PRAME targeting in clinical stages, has appointed Venkat Ramanan, Ph.D., as its Chief Financial Officer (CFO), effective immediately. Dr. Ramanan, a seasoned financial expert in biopharmaceuticals, brings over 25 years of experience from companies like Seagen, Gilead Sciences, and Amgen. His expertise includes facilitating successful product launches, establishing scalable operations in global markets, and enabling corporate transactions. Before joining Immatics, he was CFO at Anthos Therapeutics, a Novartis company. He succeeds Arnd Christ, the current CFO of Immatics.
Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics, expressed enthusiasm for Venkat’s arrival, citing his extensive experience as crucial for advancing their PRAME franchise and moving their PRAME cell therapy, anzu-cel, towards commercialization for patients with significant unmet medical needs. He also thanked Arnd Christ for his leadership and contributions to Immatics’ current standing, wishing him well in his future endeavors.
Venkat Ramanan, Ph.D., the incoming CFO of Immatics, stated that it’s a critical time to join Immatics as they approach their first commercial launch and aim to deliver their innovative PRAME cell therapy, anzu-cel, to metastatic melanoma patients. He looks forward to collaborating with the team during this growth phase, supporting the transition to a commercial-stage organization, and strengthening Immatics’ position as a leader in precision PRAME targeting, driven by a commitment to impacting cancer patients’ lives.
Dr. Ramanan’s 25+ years of experience encompass finance, strategy, and operations in both large and small biopharmaceutical companies, with a history of guiding companies through successful transformations and growth. Prior to Anthos Therapeutics, acquired by Novartis in April 2025, he was CFO at Turnstone Biologics, leading their IPO. At Seagen as Senior Vice President Finance, he oversaw finance, enabling multiple product launches, global expansion, and strategic transactions. He also held senior roles at Gilead Sciences and Amgen, starting his biopharmaceutical career as a consultant with ZS Associates. He holds a Ph.D. in Engineering Mechanics from The Ohio State University.
About Immatics
Immatics is dedicated to significantly improving the lives of cancer patients. It stands as a leader in precision PRAME targeting, a target found in over 50 cancers. Their advanced science and clinical pipeline represent the broadest PRAME franchise, encompassing the most PRAME indications and modalities, including TCR T-cell therapies and TCR bispecifics.
Immatics intends to use its website as a channel for disclosing important non-public information. Regular updates are also available on and .
Forward-Looking Statements
This press release contains forward-looking statements regarding future events or the Company’s future financial or operating performance. These statements can be identified by terms like “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”. Such statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially. These statements are based on estimates and assumptions that are inherently uncertain, and new risks and uncertainties may emerge. Factors that may cause differences include general economic conditions and other risks, uncertainties and factors set forth in the Company’s filings with the SEC. These statements are not a representation that any contemplated results will be achieved. You should not place undue reliance on them, and the Company undertakes no duty to update them. All scientific and clinical data are preliminary and subject to further quality checks.
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 74416179
Email:
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
Email:
– END –
Attachment
“`